Examination of the peginterferon+ribavirin+proteaseinhibitor combined effect for type 1 high viral load chronic hepatitis C

Trial Profile

Examination of the peginterferon+ribavirin+proteaseinhibitor combined effect for type 1 high viral load chronic hepatitis C

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Peginterferon; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top